Selpercatinib was approved for use in the U.S. in May 2020 for patients with RET-fusion positive non-small cell lung cancer, RET-fusion positive thyroid cancer, or RET-mutation positive meduallary thyroid cancer. This evidence concerns the gene RET and thyroid gland carcinoma.